Clinical trials: Urogenital
Bacterial Vaginosis
Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis
The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal®…
- Trial name
- NCT01020396
- Testing
- Metronidazole
- Where
- 37 sites in United States
- Volunteers
- 579 people
- Sponsor
- Teva Pharmaceuticals USA
Ovarian Cancer
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history.
- Trial name
- OVARD (NCT05918042)
- Where
- 24 sites in Russia
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Urinary Stone
Study of an Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease
This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.
- Trial name
- STONES (NCT04771182)
- Testing
- Enhanced Lithotripsy System
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Avvio Medical
Endometriosis
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life.
- Trial name
- DIVA (NCT01595724)
- Testing
- Visanne (Dienogest, BAY86-5258)
- Where
- 11 sites in Belarus, Egypt and 9 more
- Volunteers
- 3,006 people
- Sponsor
- Bayer
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.
- Trial name
- EVEREST-I (NCT03423979)
- Testing
- Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel
- Where
- 5 sites in Dominican Republic, Panama
- Volunteers
- 80 people
- Sponsor
- Urotronic Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Depression, Depression, Postpartum
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of…
- Conditions
- Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
- Trial name
- NCT06364488
- Testing
- TrueBlue App
- Where
- 2 sites in United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- BlueSkeye AI
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Infections, Bacterial
Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor that is being developed for the treatment of uncomplicated urinary tract infections (UTIs; acute cystitis).
- Trial name
- NCT03568942
- Testing
- Gepotidacin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
- Trial name
- NCT00040170
- Testing
- MVA-MUC1-IL2
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Transgene
Sexual Dysfunction, Physiological, Ejaculation
An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
The purpose of the study is to collect information regarding the safety of dapoxetine hydrochloride when used in clinical practice to treat men with premature ejaculation.
- Trial name
- NCT01021670
- Testing
- Dapoxetine hydrochloride, Alternate care/non-dapoxetine hydrochloride treatment(s)
- Where
- 212 sites in Austria, Finland and 4 more
- Volunteers
- 10,027 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Relapsed/Refractory Ovarian Carcinoma
Study of NTB-928 in R/R OC
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the…
- Trial name
- NCT07690189
- Testing
- NTB-928
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- TeneoSeven, Inc.
Endometriosis, Endometriosis Ovary
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
Background: Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.
- Conditions
- Endometriosis, Endometriosis Ovary, Endometriosis Externa, Endometriosis, Rectum
- Trial name
- ELTA (NCT03481842)
- Testing
- Linifanib, BIBW2992, Axitinib
- Where
- Switzerland
- Sponsor
- BioGene Pharmaceutical Ltd.
Risk of Bone Fracture Occurrences
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
- Trial name
- TREAT2 (NCT01214291)
- Testing
- Toremifene
- Where
- United States
- Sponsor
- GTx
Kidney Disease, Chronic
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Trial name
- NCT06531824
- Testing
- BI 690517, Empagliflozin
- Where
- 562 sites in United States, Argentina and 18 more
- Volunteers
- 8,371 people
- Sponsor
- Boehringer Ingelheim
Renal Failure, End Stage Renal Disease
Safety and Clinical Performance of a Dialyzer With a Modified Polysulfone Membrane
The clinical investigation will be performed to generate clinical data on clearances and removal rates (for ß2-microglobulin, myoglobin, phosphate, creatinine, and urea) as well as biocompatibility of the modified polysulfone…
- Trial name
- eMPORA (NCT03315624)
- Testing
- Dialyzer
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Injury of Kidney, Acute Renal Failure
A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 8-10 centers in the United States and Switzerland.
- Trial name
- NCT00554359
- Testing
- I5NP (a small interfering RNA)
- Where
- 11 sites in United States, Israel and 1 more
- Volunteers
- 16 people
- Sponsor
- Quark Pharmaceuticals
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Renal Impairment, Type 2 Diabetes Mellitus
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with…
- Trial name
- NCT01948986
- Testing
- Ertugliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.